Government of India and Pharma Industry Jointly Form the India Responsible Healthcare Trust
The India Brand Equity Foundation (IBEF), annouces on behalf of the Government of India and the major pharmaceutical industry organisations have come together to form the India – Responsible Healthcare Trust. This significant development has been designed to power the Brand India Pharma campaign. A one of its kind public–private partnership, the formation of the Trust represents the commitment to both drive and safeguard the interests of the Indian pharma industry.
The Trust chaired by the Commerce Secretary comprises key stakeholders, namely, the Indian Pharmaceutical Alliance (IPA), Indian Drug Manufacturers’ Association (IDMA), Bulk Drug Manufacturers Association (BDMA), Association of Biotechnology Led Enterprises (ABLE), Pharmaceutical Export Promotion Council of India (Pharmexcil) and India Brand Equity Foundation (IBEF). The Trust aims to combine both financial and non-financial resources towards a common agenda.
The Trust aims to create better awareness and develop an informed perspective about Brand India Pharma in both the domestic and global markets.
“The India – Responsible Healthcare Trust will spearhead the Brand India Pharma initiative through the second phase. The industry-government partnership is an important milestone in the campaign,” said Mr Rajeev Kher, Commerce Secretary, Government of India.
The Brand India Pharma campaign was launched under the aegis of the Department of Commerce at CPHI Japan in March 2012. The Brand India Pharma showcase has made its presence felt at prestigious events like CPHI Worldwide consistently over the past two years. The Department of Commerce along with IBEF and Pharmexcil has invested huge resources with measurable and impacting results in the first phase of the Brand India Pharma campaign.
The India – Responsible Healthcare Trust is expected to take the Brand India Pharma campaign to the next level. The primary objective of this Trust will be to position India as a Responsible Healthcare provider.
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance